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CT scan reveals diffuse circumferential gastric wall 
and omental thickening w splenomegaly
PET scan demonstrates high abdominal tumor 
burden with distant lymph nodes
Gastric biopsy demonstrates diffuse infiltration of large lymphoid cells with artifact.
(A) EBER slide reveals EBV positivity. (B) Test positive for CD20 confirms B-cell lineage.
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• People with HIV infection are at least 50 times more likely to get 
lymphoma as compared to the general population.  
• 25-40% of these lymphomas will be Burkitt Lymphoma (BL) – an 
aggressive B cell malignancy with a high proliferative rate and potentially 
fatal within months if not diagnosed and treated in a timely manner. 
• This translates to a 10-20% individual life-time risk of BL for an HIV 
infected person.
• The incidence of BL declined after the introduction of highly active 
antiretroviral therapy (HAART), but to a lesser extent than other HIV-
associated malignancies.
• Epidemiologic studies suggest the incidence of BL will increase as the HIV-
infected population ages
***
• Lymphoma in the leading cause of cancer-related deaths among HIV-
infected patients in the anti-retroviral therapy era.
• Burkitt lymphoma (BL) is a highly proliferative NHL deriving from B 
cells and with characteristic oncogenic pathways, including 
translocation in the MYC gene-- a gene that normally plays a role in 
controlling cell proliferation, differentiation and apoptosis. 
• The WHO classifies 3 different clinical variants of BL: endemic, 
sporadic and immunodeficiency-associated.
• Unlike other HIV-associated lymphomas, BL is frequently noted in 
patients with CD4 cell counts >200 and viral loads suppressed by ART
• HIV-associated BL typically presents with extra-nodal disease, mostly 
commonly the stomach
• Intra-abdominal BL may present with abdominal pain, nausea, 
vomiting, GI bleeding, bowel obstruction; fever, night sweats, weight 
loss (B symptoms), fatigue and malaise are also common.  
• Approximately 70% will present with wide spread disease (stage III or 
IV), in addition to elevated LDH and uric acid levels
• The classic “starry sky appearance” is not often seen in the 
histological examination of HIV-associated BL. Most are positive for 
Epstein Barr Virus (EBV).
• Recent studies suggest the pathobiology of HIV-associated 
lymphomas is distinct from non-HIV lymphomas.  HIV may directly 
induce B-cell activation. Further oncogenic viruses, as EBV, are more 
prevalent in HIV-associated lymphomas. 
• Survival with HIV-associated BL is approaching that of HIV-negative BL 
thanks to the development of short duration, dose intensive 
combination chemotherapy with aggressive CNS prophylaxis, the 
availability of rituximab and the implementation of effective ART
• Rare cases of IRIS- associated Burkitt Lymphoma have been reported, 
typically within 6 months after the initiation of HAART. It is unclear if 
that was the case with our patient.
A 24 yo woman with known HIV presented with 1 month of intermittent 
fevers, chills, nausea and diffuse abdominal pain most notable in the 
epigastric region.  Her symptoms acutely worsened in the last week, 
prompting her visit to the Emergency Department.
Past Medical History:
• HIV- diagnosed in 2014. Last on ART Feb-May 2019 while in jail. CD4 count 
596 (low at 26%) and HIV RNA viral count 26,400 prior to ART initiation. 
CD4 count improved to 33% with an undetectable viral load in April. 
• Chronic hepatitis C 
• Active IVDU – heroin, methamphetamines
• Tobacco dependence
Exam:
• Vitals: HR 135, RR 22, Temp 102.8 F, normotensive,SpO2>95% on room air
• Profuse sweating, notably uncomfortable
• New 2/6 holosystolic heart murmur in LUSB with no radiation
• Left lower quadrant and epigastric tenderness, negative Murphy’s sign
Labs on admission:
• Hgb 9 (baseline: 11)
• Normal complete metabolic panel
• HIV RNA viral load 55,800
• CD4 count 596, 32%
Hospital Course:
• Started on broad spectrum antibiotics for presumed endocarditis in the 
setting of active IVDU
• TTE revealed no vegetations, blood cultures negative
• CT abdomen pelvis obtained the night of admission demonstrated diffuse 
gastric thickening with evidence of omental seeding with nodularity and 
splenomegaly
• Endoscopy completed the following day f und a large nonbleeding gastric 
ulcer and diffuse gastric inflammation.  
• Pathology of endoscopic biopsies of the gastric antrum identified Diffuse 
Large B-cell Lymphoma (DLBCL) and H.pylori. 
• Immunohistochemistry test positive for Epstein Barr Virus. 
• The patient was started on Biktarvy (last use 1-3 months prior)
• PET scan was done for staging revealed advanced disease with a diffuse 
tumor burden
• MYC rearrangement detected on FISH analysis, consistent with high grade 
Burkitt lymphoma
• She completed 1 cycle of Short Course EPOCH-RR with a guarded 
prognosis. There was high concern for TLS and gastric perforation due to 
the extensive abdominal tumor burden. Fortunately, neither happened.
• Thus far, she has tolerated 3 of the anticipated 6 chemo cycles with 
relatively minor complications by comparison including bradycardia, 
frequent NSVT and neutropenia necessitating adjustments to her 
chemotherapy regimen and schedule delays. 
• Her pain control has remained a challenge in light of her ongoing IV 
substance use.
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• This case emphasizes the importance of considering lymphomas in 
the HIV positive patient presenting with subacute abdominal 
symptoms. CT abdomen pelvis with contrast, possibly endoscopy, 
should be considered as part of the work up. 
• HIV-associated BL, unlike other lymphomas,  can develop in HIV-
patients well controlled on ART
• BL is an aggressive malignancy that can be fatal within months if not 
appropriately diagnosed and treated. 
• The impact of HIV, oncogenic viruses and HAART on the lymphoma 
microenvironment is still unclear
• IRIS associated BL appears to be rare. 
A
Endoscopy shows a nonbleeding gastric ulcer>80 
mm w/diffuse gastric inflammation
B
Incidence and Survival among HIV-infected cases with BL. 
Graphs adapted from Cancer Epidemiol Biomarkers Prev; 25(9) Sept 2016. 
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